



an Open Access Journal by MDPI

Research on Biomarkers for Cardiometabolic Risk in Metabolic Syndrome

Guest Editors:

Dr. Antoaneta Trifonova Gateva

Department of Internal Medicine, Medical Faculty, Medical University Sofia, Sofia, Bulgaria

Dr. Yavor Sashov Assyov

Department of Internal Medicine, Medical Faculty, Medical University Sofia, Sofia, Bulgaria

Deadline for manuscript submissions: 10 February 2025

Message from the Guest Editors

Dear Colleagues,

A comprehensive approach that influences the main components of Metabolic syndrome is essential, especially in high-risk patients, to normalize the primary metabolic abnormalities, which will reduce the cardiovascular risk and the risk of DM2 in the long term. Recently, more and more attention has been directed to personalized medicine and an individualized approach not only in relation to therapeutic but also to preventive interventions aimed at influencing risk factors and reducing long-term complications. The personalized approach is based on the individual characteristics of individual patients, including different biomarkers and genetic variants. This Special Issue aims to collect research articles and review exploring biomarkers associated with cardiometabolic risk in individuals with metabolic syndrome, with a focus on identifying novel markers and elucidating their role in disease pathogenesis and prevention.

Dr. Antoaneta Trifonova Gateva Dr. Yavor Sashov Assyov *Guest Editors*









an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

 Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda
Ospedaliero-Universitaria, 41126 Modena, Italy
Formerly Professor of Internal Medicine, School of
Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies shown utility elucidating have for mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biochemistry and Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

Contact Us

Metabolites Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/metabolites metabolites@mdpi.com X@MetabolitesMDPI